We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Apr 20
Merck’s supplemental biologics license application (sBLA) for KEYTRUDA has been acepted by FDA as monotherapy for patients with…
06 Apr 20
Rybelsus, which is currently being reviewed by regulatory agencies, including the Japanese Pharmaceuticals and Medical Devices Agency
02 Apr 20
FDA advises consumers, patients and health care professionals to withdraw Ranitidine, following the latest studies demonstrating risk to…
31 Mar 20
Taltz is a monoclonal antibody designed to selectively bind with interleukin 17A (IL-17A) and inhibit its interaction with…
31 Mar 20
Imfinzi is the only available immunotherapy that shows survival benefit in combination with etoposide and a choice of…
23 Mar 20
Health Canada approved VOCABRIA (cabotegravir) for short-term treatment, along with CABENUVA (cabotegravir and rilpivirine extended-release)
20 Mar 20
The FDA approved the treatment following an open-label, multicentre clinical trial to evaluate the safety, efficacy, and pharmacokinetics…
12 Mar 20
The FDA indicated Opdivo 1mg/kg plus Yervoy 3mg/kg for treating HCC patients, who were previously treated with sorafenib
11 Mar 20
Janssen has signed a licensing agreement with Genmab to use its DuoBody technology platform for the production and…
06 Mar 20
DURYSTA has reduced the intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30% from…